Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $173

Benzinga · 5d ago
Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $165 to $173.